Spinal Modulation, Inc. provides medical devices research and development services. The company is based in Menlo Park, California. According to the 2002 Health Assessment on the Prevalence of Chronic Pain, severe chronic pain, as defined by the International Association for the Study of Pain, is prevalent in 10 to 13% of the adult population. Limited treatment options exist for these patients and the burden to the healthcare system is unsustainable. The Spinal Modulation AxiumTM Neurostimulator System is a next-generation intraspinal neuromodulation therapy that stimulates the dorsal root ganglion (DRG) to provide a new pain management option. It has shown promising results in managing chronic intractable leg pain, as well as difficult-to-target anatomies such as the back and foot. By stimulating the DRG, therapy can be adjusted to cover either broad or specific areas of pain throughout the torso and legs, while limiting uncomfortable postural effects typically experienced with other spinal cord stimulators.

St. Jude Medical Luxembourg Holding SMI SARL, part of Abbott Laboratories, is a Luxembourgish company. The firm manufactures and distributes medical equipment and devices.

Boston Scientific Neuromodulation Corp. offers implantable pain management devices for neuromodulation. The company is headquartered in Marlborough, MA.

SmartImplantSystems is a medical device company involved in the development of sensor-driven spine implants for the treatment of chronic back pain. In January 2014, Dr. Nazmi Peyman, a pain specialist, invented and patented the technology. In 2016 Dr. Peyman and Dr. Omid Souresrafil, an internal medicine doctor and medical device startup expert, founded the company to provide more advanced real solutions for long-term back pain sufferers. These are patients who have had little or no success with other pain management treatments. Once approved, we will offer patients relief to undertake simple daily tasks free of their discomfort. Patients can then live normal lives, free of the debilitating pain associated with spinal cord injuries and arthritis.

GiMer Medical is a provider of electrical stimulation technology. They focus on developing ultra high-frequency spinal cord stimulation devices that can address chronic pain, enabling clients to relieve the pain. Their product includes neuro block and O-Armilla. The customer queries are addressed through phone, online form, and email. Their updated news is imported into the website.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN.

Advanced Neuromodulation Systems, Inc. manufactured, designed, developed and marketed spinal cord stimulation devices. Their products included implantable neurostimulation devices, which deliver electric current directly to targeted nerves and implantable drug pumps. The company was registered in May 3, 1979 and was headquartered in St. Paul, MN.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

Q-State Biosciences has developed an all-optical electrophysiology platform for controlling and recording activity in electrically active cells: primary and human iPSC-derived cardiomyocytes and neurons. The platform combines proprietary ultrasensitive optogenetic actuators, genetically encoded voltage indicators, stem cell technology and advanced optical imaging. Q-State Biosciences uses custom instrumentation and software to probe cellular physiology with sub-micron spatial resolution and sub-millisecond temporal resolution. Q-State technology probes dynamic cellular physiology with far higher throughput and information content than are achieved with manual patch clamp, multi electrode arrays, or calcium- or voltage-sensitive dyes.

Manufactures pharmaceuticals

TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma).\nTM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies.\nIn addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.

AxoGen, Inc. engages in the development of treatment options for the repair of peripheral nerve injuries. It offers AVANCE Nerve Graft, a human allograft nerve that is used for the repair, replacement, and reconstruction of damaged peripheral nerves. The company accepts orders through phone, fax, or email. It serves surgeons. AxoGen has a strategic tissue recovery partnership with American Tissue Services Foundation (ATSF). The company was founded in 2002 and is based in Alachua, Florida.

Stimwave LLC develops and commercializes wireless, micro size, injectable devices for the treatment of chronic back and leg pain. Its products include stimulators, wearable antrnna and IOS programmer. The firm provides patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. The company was founded by Laura Tyler Perryman in 2010 and is headquartered in Fort Lauderdale, FL.

AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada.

Pharnext is an advanced clinical-stage biopharmaceutical company founded in April 2007 by renowned scientists and entrepreneurs including Professor Daniel Cohen and collaborators, pioneers in modern genomics. The company develops new therapeutics for neurodegenerative diseases - orphan and common – where there are currently no cures and existing therapies available. Pharnext is the pioneer of a new paradigm for the discovery of medicinal drugs: PLEOTHERAPY™. The R&D approach protected by Pharnext systemizes new uses of approved drugs. It is based on network pharmacology utilizing complex and extensive genomic data to identify the thousands of molecules possibly involved in a disease. From this disease molecular network, Pharnext deduces synergistic combinations of drugs already approved but for unrelated indications. These novel therapeutics called PLEODRUG™ are then developed at new optimal doses and under new formulations. They offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The proof of concept of the PLEOTHERAPY approach was obtained with PLEODRUG PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) through positive and consistent Phase 2 and Phase 3 results. PLEODRUG PXT864 generated encouraging Phase 2 data in Alzheimer’s disease. They also plan to develop the same agent in other orphan and common neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

Part of Medtronic Plc, Warsaw Orthopedic, Inc. is a company headquartered in the United States that operates orthopedic center.